Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN305-102 follow-up in high-risk renal transplant recipients
2012-005767-27Phase 2Completed
- Sponsor
- Opsona Therapeutics
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tomaralimab in Kidney Graft Dysfunction (DGF), delayed graft function (DGF) and kidney allograft rejection (2 arms), sponsored by Opsona Therapeutics. Primary endpoint: Incidence of biopsy-proven allograft rejection or graft loss. Started Nov 2013; status: completed.
02
Drugs
tomaralimab
03
Conditions
Kidney Graft Dysfunction (DGF)delayed graft function (DGF)kidney allograft rejection
Beyond the preview
Go deeper on 2012-005767-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005767-27.